Active substance
Fosfomycin
- SFDA 6
- US FDA 10
- Health Canada 3
- US price lines 1
- NHS prices 1
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Fomicyt | 40 mg/ml | Powder for solution for infusion · Intravenous use | 10 Bottle | SAR 1356.65 | NCE · Prescription | Infectopharm Arzneimittel und Consilium GmbH | Valid |
| Fomicyt | 40 mg/ml | Powder for solution for infusion · Intravenous use | 10 Bottle | SAR 2713.35 | NCE · Prescription | Infectopharm Arzneimittel und Consilium GmbH | Valid |
| Fomicyt | 40 mg/ml | Powder for solution for infusion · Intravenous use | 10 Bottle | SAR 678.30 | NCE · Prescription | Infectopharm Arzneimittel und Consilium GmbH | Valid |
| MONUROL | 3.0 g | Granules · Oral use | 2 Sachet | SAR 64.50 | NCE · Prescription | ZAMBON SWITZERLAND LTD | Valid |
| MONUROL 3G SACHETS | 3 g | Granules · Oral use | 1 Sachet | SAR 32.25 | NCE · Prescription | ZAMBON SWITZERLAND LTD | Valid |
| UNAIRA 3GM SACHET | 3 g | Granules for oral solution · Oral use | 1 Sachet | SAR 29.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
Indications — CHI Daman Drug Formulary
LOWER URINARY TRACT INFECTIONS; OSTEOMYELITIS; RECURRENT URINARY TRACT INFECTIONS (UTI)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | XIROMED | Prescription | 6 Oct 2020 |
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | ALKEM LABS LTD | Prescription | 21 Oct 2021 |
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | CIPLA | Prescription | 26 Jan 2022 |
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | AMNEAL | Prescription | 25 Mar 2024 |
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | PRECISION DOSE INC | Prescription | 3 Jun 2025 |
| CONTEPO | EQ 6GM BASE/VIAL | powder · intravenous | MEITHEAL | Prescription | 22 Oct 2025 |
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | AUROBINDO PHARMA LTD | Prescription | 14 Nov 2025 |
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | AUCTA | Prescription | 9 Apr 2026 |
| FOSFOMYCIN TROMETHAMINE | EQ 3GM BASE/PACKET | for solution · oral | NOVITIUM PHARMA | Prescription | 12 Aug 2026 |
| MONUROL | EQ 3GM BASE/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | for solution · oral | ZAMBON SPA | Discontinued | 19 Dec 1996 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| IVOZFO | 02488086 | 4 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | VERITY PHARMACEUTICALS INC. |
| JAMP FOSFOMYCIN | 02473801 | 3 G / SACHET | POWDER FOR SOLUTION · ORAL | JAMP PHARMA CORPORATION |
| MONUROL | 02240335 | 3 G / SACHET | POWDER FOR SOLUTION · ORAL | KNIGHT THERAPEUTICS INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FOSFOMYCIN 3 GM SACHET | $26.22036 | per EA | 30 Sep 2026 |
| NHS Drug Tariff | Fosfomycin 3g granules for oral solution sachets | £5.10 | 1 sachet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.3. Reserve group antibiotics · complementary
Carbapenem resistant Acinetobacter baumannii; Carbapenem-resistant Pseudomonas aeruginosa; Other carbapenem resistant Enterobacterales
Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.